ArticleOncology and therapy2025
Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis.
Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE).ESMO real world data and digital oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with node-positive, high-risk, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) can be treated with 2 years of abemaciclib plus endocrine therapy (ET) to improve invasive disease-free survival (IDFS; hazard ratio 0.68; absolute 7.6% 5-year IDFS benefit) over ET alone as observed in the monarchE trial. Most adverse events (AEs) from abemaciclib occurred early in treatment and could be managed with dose reductions while maintaining efficacy. Describing adjuvant abemaciclib dosing patterns and early treatment persistence in patients in a real-world node-positive EBC cohort provides new evidence on abemaciclib administration in clinical practice and may inform AE management.
methodsUsing the Flatiron Health Research Database de-identified data from October 2021 to February 2023, this retrospective study included patients aged ≥ 18 years with node-positive, HR+, HER2- EBC without prior CDK4/6 inhibitor exposure who initiated adjuvant abemaciclib at 150 mg twice daily (BID) and had ≥ 3 months follow-up. Dose modifications were identified. The persistence rate (%) and reasons for treatment discontinuation were described.
resultsAmong 354 patients (99.7% female), 88.1% of patients continued abemaciclib beyond 3 months. Dose reductions were observed in 50.8% of patients. Median time to first dose reduction was 59 days (IQR 35, 99). Of the patients with a dose reduction, 93.3% continued abemaciclib beyond 3 months. Among patients who discontinued abemaciclib because of AEs within 3 months of initiation without evidence of reinitiation (n = 40), 70.0% had no evidence of a dose reduction.
conclusionEighty-eight percent of patients continued adjuvant abemaciclib beyond 3 months, demonstrating high early persistence and tolerance of abemaciclib in patients with node-positive EBC in a real-world clinical practice cohort. Persistence was 93.3% among patients who had a dose reduction, suggesting that timely dose adjustments, when needed, can promote early persistence on abemaciclib, particularly when patient-felt AEs are most frequent and can be effectively managed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.